Michal Bar-Natan, M.D. at Leukemia ...

Dr. Michal Bar-Natan, MD

Claim this profile

Icahn School of Medicine at Mount Sinai

Studies Burkitt's Leukemia
Studies Leukemia
5 reported clinical trials
21 drugs studied

Area of expertise

1

Burkitt's Leukemia

Michal Bar-Natan, MD has run 3 trials for Burkitt's Leukemia. Some of their research focus areas include:

BCR-ABL1 positive
CD19 positive
CRLF2 positive
2

Leukemia

Michal Bar-Natan, MD has run 3 trials for Leukemia. Some of their research focus areas include:

BCR-ABL1 positive
CD19 positive
CRLF2 positive

Affiliated Hospitals

Image of trial facility.

Mount Sinai Hospital

Image of trial facility.

Icahn School Of Medicine At Mount Sinai

Clinical Trials Michal Bar-Natan, MD is currently running

Image of trial facility.

ABL001 Combo Therapy

for Leukemia

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 40-65 people will take part in this research study. * ABL001 * Dasatinib (Sprycel®) * Prednisone * Blinatumomab

Recruiting

1 award

Phase 1

Image of trial facility.

Inotuzumab Ozogamicin + Chemotherapy

for Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as \[intervention\], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

Recruiting

2 awards

Phase 3

3 criteria

More about Michal Bar-Natan, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Michal Bar-Natan, MD has experience with

  • Cytarabine
  • ABL001
  • Dasatinib
  • Prednisone
  • Mutant CALR-peptide Based Vaccine
  • Allopurinol

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Michal Bar-Natan, MD specialize in?

Is Michal Bar-Natan, MD currently recruiting for clinical trials?

Are there any treatments that Michal Bar-Natan, MD has studied deeply?

What is the best way to schedule an appointment with Michal Bar-Natan, MD?

What is the office address of Michal Bar-Natan, MD?

Is there any support for travel costs?